131.83
price down icon0.14%   -0.19
after-market 시간 외 거래: 131.83
loading
전일 마감가:
$132.02
열려 있는:
$133.16
하루 거래량:
470.11K
Relative Volume:
0.39
시가총액:
$13.05B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
44.69
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-2.44%
1개월 성능:
+4.17%
6개월 성능:
-9.63%
1년 성능:
-9.51%
1일 변동 폭
Value
$131.51
$133.80
1주일 범위
Value
$131.07
$136.25
52주 변동 폭
Value
$84.23
$157.98

뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile

Name
명칭
Neurocrine Biosciences Inc
Name
전화
(858) 617-7600
Name
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
직원
1,800
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
NBIX's Discussions on Twitter

NBIX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
131.83 13.37B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
147.37 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.44 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.53 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.31 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
293.12 13.43B 2.99B 1.21B 1.13B 25.06

뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-10 개시 Goldman Buy
2025-04-15 업그레이드 Needham Hold → Buy
2025-04-14 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2025-02-11 개시 Deutsche Bank Hold
2024-10-10 재개 Raymond James Outperform
2024-08-29 업그레이드 Piper Sandler Neutral → Overweight
2024-04-24 업그레이드 Wells Fargo Equal Weight → Overweight
2023-12-13 재개 Citigroup Neutral
2023-12-12 개시 Deutsche Bank Buy
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-21 재확인 Mizuho Neutral
2023-07-24 업그레이드 SVB Securities Market Perform → Outperform
2023-07-06 업그레이드 BMO Capital Markets Underperform → Market Perform
2023-05-04 업그레이드 Guggenheim Neutral → Buy
2023-03-30 업그레이드 Canaccord Genuity Hold → Buy
2023-03-03 업그레이드 Evercore ISI In-line → Outperform
2023-02-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-11-14 다운그레이드 Evercore ISI Outperform → In-line
2022-10-11 개시 UBS Buy
2022-09-26 개시 Wells Fargo Equal Weight
2022-06-06 재개 Jefferies Buy
2022-03-03 다운그레이드 Piper Sandler Overweight → Neutral
2022-02-25 업그레이드 Goldman Neutral → Buy
2022-01-18 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-11-19 개시 BMO Capital Markets Underperform
2021-11-17 업그레이드 JP Morgan Neutral → Overweight
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-08-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-05-18 재개 Goldman Neutral
2021-05-06 업그레이드 Barclays Equal Weight → Overweight
2021-02-02 개시 Raymond James Outperform
2020-09-30 개시 The Benchmark Company Hold
2020-08-04 다운그레이드 JP Morgan Overweight → Neutral
2020-06-29 다운그레이드 Goldman Buy → Neutral
2020-06-09 개시 Wedbush Outperform
2020-03-06 개시 Citigroup Buy
2020-02-27 개시 Barclays Equal Weight
2020-02-24 개시 William Blair Outperform
2020-02-06 개시 Mizuho Neutral
2020-02-05 재확인 H.C. Wainwright Buy
2019-12-13 다운그레이드 Credit Suisse Outperform → Neutral
2019-08-07 개시 RBC Capital Mkts Outperform
2019-07-16 개시 Oppenheimer Outperform
2019-06-05 개시 Guggenheim Neutral
2019-05-21 개시 Credit Suisse Outperform
2019-04-22 업그레이드 JP Morgan Neutral → Overweight
2019-04-12 개시 Evercore ISI Outperform
2019-02-06 재확인 BofA/Merrill Buy
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-12-13 개시 Goldman Buy
2018-11-21 개시 Canaccord Genuity Buy
모두보기

뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스

pulisher
04:59 AM

Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

04:59 AM
pulisher
09:17 AM

Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada

09:17 AM
pulisher
Jul 20, 2025

What analysts say about Neurocrine Biosciences Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Is Neurocrine Biosciences Inc. a good long term investmentExplosive capital gains - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Neurocrine Biosciences Inc. stock priceConsistently high yield - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

Neurocrine Biosciences Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional

Jul 19, 2025
pulisher
Jul 18, 2025

Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Neurocrine reports positive results from Crenessity trial - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares registry data showing CAH treatment challenges - StreetInsider

Jul 15, 2025
pulisher
Jul 15, 2025

New Registry Data Reveals 95% of CAH Patients Struggle with Current Treatments, Highlighting Urgent Need - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Breakthrough Clinical Data: CRENESSITY Achieves Major Weight Improvements in Both Adult and Child CAH Patients - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive one-year data for CAH treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data from study of Crenessity - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

CRENESSITY's Groundbreaking CAH Data Positions Neurocrine Biosciences for Dominance in a High-Impact Market - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive one-year data for CAH treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

New Clinical Data: CRENESSITY Achieves Breakthrough 30% Steroid Reduction in Adult CAH Treatment - Stock Titan

Jul 14, 2025
pulisher
Jul 13, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Given New $174.00 Price Target at UBS Group - MarketBeat

Jul 13, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences: Insider Selling StormShould Investors Be Alarmed? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences Insider Unloads $7.8mln in Shares According to Recent SEC Filing - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List - Insider Monkey

Jul 11, 2025
pulisher
Jul 10, 2025

Neurocrine Biosciences (NBIX) Soars 1.06% on Positive Analyst Ratings - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results - Eastern Progress

Jul 10, 2025
pulisher
Jul 10, 2025

11 Best Debt-Free Stocks to Invest in Right Now - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

CRF1 and CRF2 antagonists disclosed in Neurocrine Biosciences patent - BioWorld MedTech

Jul 10, 2025
pulisher
Jul 10, 2025

Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Neurocrine initiated with a Buy at Goldman Sachs - TipRanks

Jul 10, 2025

뉴로크린 바이오사이언시스 (NBIX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$293.12
price up icon 0.38%
drug_manufacturers_specialty_generic RDY
$14.55
price up icon 0.48%
$8.90
price up icon 0.23%
$16.31
price up icon 1.56%
$14.68
price down icon 0.68%
자본화:     |  볼륨(24시간):